Abiopharma

🔍 Rodman David Malcom (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 10,053 shares of Common Stock at $1.08 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 81,888.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 3,629 shares of Common Stock at $15.44 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 85,517.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9,347 shares of Common Stock at $10.2 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 94,864.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,168 shares of Common Stock at $16.0 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 115,032.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 24,193 shares of Common Stock at $14.25 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 139,225.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 70,037 shares of Common Stock at $35.8656 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 69,188.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 28,038 shares of Common Stock at $1.08 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 97,226.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 10,121 shares of Common Stock at $15.44 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 107,347.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 26,069 shares of Common Stock at $10.2 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 133,416.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 53,630 shares of Common Stock at $16.0 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 187,046.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 67,473 shares of Common Stock at $14.25 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 254,519.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 139,245 shares of Common Stock at $34.8275 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 115,274.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 53,470 shares of Common Stock at $35.5256 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,804.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 10,053 shares of Stock Option at $1.08 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2032-07-11 | equity_swap_involved: 0 | shares_owned_after: 72,478.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 3,629 shares of Stock Option at $15.44 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2033-03-17 | equity_swap_involved: 0 | shares_owned_after: 16,371.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 9,347 shares of Stock Option at $10.2 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2035-02-13 | equity_swap_involved: 0 | shares_owned_after: 160,653.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 20,168 shares of Stock Option at $16.0 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2033-02-09 | equity_swap_involved: 0 | shares_owned_after: 84,018.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 24,193 shares of Stock Option at $14.25 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2034-02-13 | equity_swap_involved: 0 | shares_owned_after: 175,807.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 28,038 shares of Stock Option at $1.08 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2032-07-11 | equity_swap_involved: 0 | shares_owned_after: 44,440.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 10,121 shares of Stock Option at $15.44 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2033-03-17 | equity_swap_involved: 0 | shares_owned_after: 6,250.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 26,069 shares of Stock Option at $10.2 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2035-02-13 | equity_swap_involved: 0 | shares_owned_after: 134,584.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 53,630 shares of Stock Option at $16.0 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2033-02-09 | equity_swap_involved: 0 | shares_owned_after: 30,388.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 67,473 shares of Stock Option at $14.25 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2034-02-13 | equity_swap_involved: 0 | shares_owned_after: 108,334.00 | transaction_form_type: 4 | Footnotes: F1, F6

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• F2: This balance includes 680 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
• F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6550 to $36.4522. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
• F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.2100 to $35.2021. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
• F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.2100 to $35.7700. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
• F6: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
• F7: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.